Catestatin (chromogranin A344-364) is a novel cardiosuppressive agent: Inhibition of isoproterenol and endothelin signaling in the frog heart

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 295, Issue 1, 2008, Pages

  Mazza, Rosa ^a   Gattuso, Alfonsina ^a   Mannarino, Cinzia ^a   Brar, Bhawanjit K ^b   Barbieri, Sandra Francesca ^a   Tota, Bruno ^a   Mahata, Sushil K ^b  

^a UNIVERSITY OF CALABRIA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Avascular heart; Chromogranin A; Endocardial endothelium; Inotropic agents; Myocardial contractility

Indexed keywords

CATESTATIN; CHROMOGRANIN A; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; GUANYLATE CYCLASE INHIBITOR; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N(G) METHYLARGININE; PHOSPHOLAMBAN; UNCLASSIFIED DRUG; 1H (1,2,4)OXADIAZOLO(4,3 A)QUINOXALIN 1 ONE; 1H-(1,2,4)OXADIAZOLO(4,3-A)QUINOXALIN-1-ONE; CALCIUM BINDING PROTEIN; CARDIOTONIC AGENT; CHROMOGRANIN A (344 364); CHROMOGRANIN A (344-364); ENZYME INHIBITOR; GUANYLATE CYCLASE; NITRIC OXIDE SYNTHASE; OLIGOPEPTIDE; OXADIAZOLE DERIVATIVE; PEPTIDE FRAGMENT; PIPERIDINE DERIVATIVE; QUINOXALINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG PROTEIN BINDING; FEMALE; FROG; HEART; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART PERFORMANCE; HEART STROKE VOLUME; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANIMAL; CATTLE; CHEMICAL PHENOMENA; DRUG ANTAGONISM; HEART CONTRACTION; HEART MUSCLE; HUMAN; IN VITRO STUDY; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; CALCIUM-BINDING PROTEINS; CARDIOTONIC AGENTS; CATTLE; CHROMOGRANIN A; DEPRESSION, CHEMICAL; ENDOTHELIN-1; ENZYME INHIBITORS; FEMALE; GUANYLATE CYCLASE; HUMANS; ISOPROTERENOL; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; NITRIC OXIDE SYNTHASE; OLIGOPEPTIDES; OMEGA-N-METHYLARGININE; OXADIAZOLES; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PIPERIDINES; QUINOXALINES; RANA ESCULENTA; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; SIGNAL TRANSDUCTION; STROKE VOLUME;

EID: 49849084465     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00172.2008     Document Type: Article

References (58)

1. Aardal S, Helle KB. The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept 41: 9-18, 1992.
2. Aardal S, Helle KB, Elsayed S, Reed RK, Serck-Hanssen G. Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments. J Neuroendocrinol 5: 405-412, 1993.
3. Aggeli IK, Gaitanaki C, Lazou A, Beis I. Activation of multiple MAPK pathways (ERKs, JNKs, p38-MAPK) by diverse stimuli in the amphibian heart. Mol Cell Biochem 221: 63-69, 2001.
4. Aggeli IK, Gaitanaki C, Lazou A, Beis I. Alpha(1)- and beta-adrenoceptor stimulation differentially activate p38-MAPK and atrial natriuretic peptide production in the perfused amphibian heart. J Exp Biol 205: 2387-2397, 2002.
5. Blois A, Srebro B, Mandalà M, Corti A, Helle KB, Serck-Hanssen G. The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells. Regul Pept 135: 78-84, 2006.
6. Bourgeois P, Dupont W, Vaillant R. Estimation du taux des catecholamines circulantes chez la Grenouille a l'aide d'une technique de dosage radio-enzymatique. C R Acad Sci Paris 287: 1149-1152, 1978.
7. Brar BK, Jonassen AK, Egorina EM, Chen A, Negro A, Perrin MH, Mjøs OD, Latchman DS, Lee KF, Vale W. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology 145: 24-35, 2004.
8. Brekke JF, Osol GJ, Helle KB. N-terminal chromogranin-derived peptides as dilators of bovine coronary resistance arteries. Regul Pept 105: 93-100, 2002.
9. Brunner F, Bras-Silva C, Cerdeira AS, Leite-Moreira AF. Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacol Ther 111: 508-531, 2006.
10. Brutsaert DL, Meulemans AL, Sipido KR, Sys SU. Effects of damaging the endocardial surface on the mechanical performance of isolated cardiac muscle. Circ Res 62: 358-366,1988.
11. Brutsaert DL. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev 83: 59-115, 2003.
12. Bueno OF, Molkentin JD. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res 91: 776-781, 2002.
13. Cappello S, Angelone T, Tota B, Pagliaro P, Penna C, Rastaldo R, Corti A, Losano G, Cerra MC. Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signalling mechanism. Am J Physiol Heart Circ Physiol 293: H719-H727, 2007.
14. Carlsten A, Poupa O, Winell S. Cardiac lesions in the frog induced by adrenaline. Acta Pharmac Toxic 47: 359-364, 1980.
15. Ceconi C, Ferrari R, Bachetti T, Opasich C, Volterrani M, Colombo B, Parrinello G, Corti A. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J 23: 967-974, 2002.
16. Cerra MC, De Iuri L, Angelone T, Corti A, Tota B. Recombinant N-terminal fragments of chromogranin-A modulate cardiac function of the Langendorff-perfused rat heart. Basic Res Cardiol 101: 43-52, 2006.
17. Corti A, Mannarino C, Mazza R, Angelone T, Longhi R, Tota B. Chromogranin A N-terminal fragments vasostatin-1 and the synthetic CGA 7-57 peptide act as cardiostatins on the isolated working frog heart. Gen Comp Endocrinol 136: 217-224, 2004.
18. D'Orleans-Juste P, Labonte J, Bkaily G, Choufani S, Plante M, Honoré JC. Function of the endothelin(B) receptor in cardiovascular physiology and pathophysiology. Pharmacol Ther 95: 221-238, 2002.
19. Fan J, Shuba YM, Morad M. Regulation of cardiac sodium-calcium exchanger by beta-adrenergic agonists. Proc Natl Acad Sci USA 93: 5527-5532, 1996.
20. Gallo MP, Levi RC, Ramella R, Brero A, Boero O, Tota B, Alloatti G. Endothelium-derived nitric oxide mediates the anti-adrenergic effect of human vasostatin-1 (CgA 1-76) in rat ventricular myocardium. Am J Physiol Heart Circ Physiol 292: H2906-H2912, 2007.
21. Gattuso A, Mazza R, Pellegrino D, Tota B. Endocardial endothelium mediates luminal ACh-NO signaling in isolated frog heart. Am J Physiol Heart Circ Physiol 276: H633-H641, 1999.
22. 2+ current trigger. J Physiol 556: 463-480, 2004.
23. Glattard E, Angelone T, Strub JM, Corti A, Aunis D, Tota B, Metz-Boutigue MH, Goumon Y. Characterization of natural vasostatin- containing peptides in rat heart. Febs J 273: 3311-3321, 2006.
24. Helle KB, Corti A, Metz-Boutigue MH, Tota B. The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci 64: 2863-2886, 2007.
25. Imbrogno S, Angelone T, Corti A, Adamo C, Helle KB, Tota B. Influence of vasostatins, the chromogranin A-derived peptides, on the working heart of the eel (Anguilla anguilla): negative inotropy and mechanism of action. Gen Comp Endocrinol 139: 20-28, 2004.
26. Kennedy BP, Mahata SK, O'Connor DT, Ziegler MG. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides 19: 1241-1248, 1998.
27. Koeslag JH, Saunders PT, Wessels JA. The chromogranins and the counter-regulatory hormones: do they make homeostatic sense? J Physiol 517: 643-649, 1999.
28. Leite-Moreira AF, Bras-Silva C. Inotropic effects of ETB receptor stimulation and their modulation by endocardial endothelium, NO, and prostaglandins. Am J Physiol Heart Circ Physiol 287: H1194-H1199, 2004.
29. Lillie EO, Mahata M, Khandrika S, Rao F, Bundey RA, Wen G, Chen Y, Taupenot L, Smith DW, Mahata SK, Ziegler MG, Cockburn M, Schork NJ, O'Connor DT. Heredity of endothelin secretion: human twin studies reveal the influence of polymorphism at the chromogranin A locus, a novel determinant of endothelial function. Circulation 115: 2282-2291, 2007.
30. Liu S, Premont RT, Kontos CD, Zhu S, Rochey DC. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med 11: 952-958, 2005.
31. Loewi O. Quantitative und qualitative untersuchungen uber den sympaticusstoff. Pflugers Arch Gesamte Physiol 237: 504-14, 1936.
32. Loewi O. Ubertragbarkeit der Herznervenwirkung. Pflugers Arch Gesamte Physiol 189: 239-242, 1921.
33. Mahapatra NR, Mahata M, Mahata SK, O'Connor DT. The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters. J Hypertens 24: 895-904, 2006.
34. Mahapatra NR, O'Connor DT, Vaingankar SM, Hikim AP, Mahata M, Ray S, Staite E, Wu H, Gu Y, Dalton N, Kennedy BP, Ziegler MG, Ross J, Mahata SK. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 115: 1942-1952, 2005.
35. Mahata SK, Mahapatra NR, Mahata M, Wang TC, Kennedy BP, Ziegler MG, O'Connor DT. Catecholamine secretory vesicle stimulus-transcription coupling in vivo. Demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin. J Biol Chem 278: 32058-32067, 2003.
36. 344-364) acts at the receptor to prevent nicotinic cholinergic tolerance. J Biol Chem 274: 2920-2928, 1999.
37. Mahata SK, Mahata M, Wakade AR, O'Connor DT. Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A344-364): Identification of amino acid residues crucial for activity. Mol Endocrinol 14: 1525-1535, 2000.
38. Mahata SK, Mahata M, Wen G, Wong WB, Mahapatra NR, Hamilton BA, O'Connor DT. The catecholamine release-inhibitory "catestatin" fragment of chromogranin a: naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses. Mol Pharmacol 66: 1180-1191, 2004.
39. Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Parmer RJ. Novel autocrine feedback control of catecholamine release. A discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Inves 100: 1623-1633, 1997.
40. Mahata SK. Catestatin: the catecholamine release inhibitory peptide: a structural and functional overview. Curr Med Chem Immun Endoc Metab Agents 4: 221-234, 2004.
41. Marasciulo FL, Montagnani M, Potenza MA. Endothelin-1: the yin and yang on vascular function. Curr Med Chem 13: 1655-1665, 2006.
42. Mazza R, Mannarino C, Imbrogno S, Barbieri SF, Adamo C, Angelone T, Corti A, Tota B. Crucial role of cytoskeleton reorganization in the negative inotropic effect of chromogranin A-derived peptides in eel and frog hearts. Regul Pept 138: 145-151, 2007.
43. Muldoon LL, Rodland KD, Forsythe ML, Magun BE. Stimulation of phosphatidylinositol hydrolysis, diacylglycerol release, and gene expression in response to endothelin, a potent new agonist for fibroblasts and smooth muscle cells. J Biol Chem 264: 8529-8536, 1989.
44. O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 20: 1335-1345, 2002.
45. Philipp S, Critz SD, Cui L, Solodushko V, Cohen MV, Downey JM. Localizing extracellular signal-regulated kinase (ERK) in pharmacological preconditioning's trigger pathway. Basic Res Cardiol 101: 159-167, 2006.
46. Pieroni M, Corti A, Tota B, Curnis F, Angelone T, Colombo B, Cerra MC, Bellocci F, Crea F, Maseri A. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 29: 1117-1127, 2007.
47. Rona G, Chappel CI, Balasz T, Gaudry R. Severe myocardial necrosis produced by isoproterenol in the rat. Arch Int Pharmacodyn Ther 122: 123-128, 1959.
48. Scotland R, Vallance P, Ahluwalia A. Endothelin alters the reactivity of vasa vasorum: mechanisms and implications for conduit vessel physiology and pathophysiology. Br J Pharmacol 128: 1229-1234, 1999.
49. 2+ current in frog ventricular myocytes. Br J Pharmacol 121: 1277-1286, 1997.
50. Slack JP, Grupp IL, Luo W, Kranias EG. Phospholamban ablation enhances relaxation in the murine soleus. Am J Physiol Cell Physiol 273: C1-C6, 1997.
51. Sys SU, Pellegrino D, Mazza R, Gattuso A, Andries LJ, Tota B. Endocardial endothelium in the avascular heart of the frog: morphology and role of nitric oxide. J Exp Biol 200: 3109-3118, 1997.
52. Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ, Barchas JD. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 324: 476-478, 1986.
53. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. New Engl J Med 348: 1134-1149, 2003.
54. Tota B, Mazza R, Angelone T, Nullans G, Metz-Boutigue MH, Aunis D, Helle KB. Peptides from the N-terminal domain of chromogranin A (vasostatins) exert negative inotropic effects in the isolated frog heart. Regul Pept 114: 91-99, 2003.
55. Vesely DL. Which of the cardiac natriuretic peptides is most effective for the treatment of congestive heart failure, renal failure and cancer? Clin Exp Pharmacol Physiol 33: 169-76, 2006.
56. Will H, Kuttner I, Kemsies C, Vetter R, Schubert E. Comparative analysis of phospholamban phosphorylation in crude membranes of vertebrate hearts. Experientia 41: 1052-1054, 1985.
57. Winkler H, Fischer-Colbrie R. The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 49: 497-528, 1992.
58. Yamaguchi T, Murata Y, Fujiyoshi Y, Doi T. Regulated interaction of endothelin B receptor with caveolin-1. Eur J Biochem 270: 1816-1827, 2003.